|
|
Vaccine Comparison
|
Adacel |
| Vaccine Information |
- Vaccine Name: Adacel
- Product Name: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed
- Tradename: Adacel
- Manufacturer: Sanofi Pasteur, Ltd (USA: License #1726)
- Vaccine Ontology ID: VO_0000005
- CDC CVX code: 20, 115
- Type: Toxoid vaccine
- Status: Licensed
- Location Licensed: USA: License #1726; Canada
- Host Species for Licensed Use: Human
- Antigen: Pertussis
- Adjuvant:
- Preparation: Clostridium tetani is grown in modified Mueller-Miller casamino acid medium without beef heart infusion. Tetanus toxin is detoxified with formaldehyde and purified by ammonium sulfate fractionation and diafiltration. Diphtheria and tetanus toxoids are individually adsorbed onto aluminum phosphate (FDA: Adacel).
- Immunization Route: Intramuscular injection (i.m.)
- Storage: Adacel vaccine should be stored at 2° to 8°C (35° to 46°F). DO NOT FREEZE
- Approved Age for Licensed Use: Adacel vaccine is indicated for active booster immunization for the prevention of tetanus, diphtheria and pertussis as a single dose in persons 11 through 64 years of age.
- Contraindication: A severe allergic reaction (e.g., anaphylaxis) after a previous dose of Adacel vaccine or any other tetanus toxoid, diphtheria toxoid or pertussis containing vaccine or any other component of this vaccine is a contraindication to vaccination with Adacel vaccine (FDA: Adacel).
- Description: It is a sterile liquid suspension of tetanus and diphtheria toxoids and acellular pertussis components adsorbed onto aluminum phosphate, for intramuscular administration.
|
| References |
FDA: Adacel: FDA: Adacel [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172481.htm]
|
|
Boostrix |
| Vaccine Information |
- Vaccine Name: Boostrix
- Product Name: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed
- Tradename: Boostrix
- Manufacturer: GlaxoSmithKline Biologicals
- Vaccine Ontology ID: VO_0000015
- CDC CVX code: 20, 115
- Type: Toxoid vaccine
- Status: Licensed
- Location Licensed: USA (License #1617)
- Host Species for Licensed Use: Human
- Adjuvant:
- Preparation: Tetanus toxin is produced by growing Clostridium tetani in a modified Latham medium derived from bovine casein. Toxins are detoxified with formaldehyde, concentrated by ultrafiltration, and purified by precipitation, dialysis, and sterile filtration (FDA: Boostrix).
- Immunization Route: Intramuscular injection (i.m.)
- Storage: Store refrigerated between 2º and 8ºC (36º and 46ºF). Do not freeze.
- Approved Age for Licensed Use: BOOSTRIX is approved for use in individuals 10 through 64 years of age
- Contraindication: A severe allergic reaction after a previous dose of any tetanus toxoid-diphtheria toxoid or pertussis antigen containing vaccine or any component of this vaccine is a contraindication to administration of BOOSTRIX (FDA: Boostrix).
- Description: BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) is a noninfectious, sterile, vaccine for intramuscular administration. It contains tetanus toxoid, diphtheria toxoid, and pertussis antigens (inactivated pertussis toxin [PT] and formaldehyde-treated filamentous hemagglutinin [FHA] and pertactin). The antigens are the same as those in INFANRIX, but BOOSTRIX is formulated with reduced quantities of these antigens (FDA: Boostrix).
|
| References |
FDA: Boostrix: FDA: Boostrix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172925.htm]
|
|
DAPTACEL |
| Vaccine Information |
- Vaccine Name: DAPTACEL
- Product Name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
- Tradename: DAPTACEL
- Manufacturer: Sanofi Pasteur, Ltd.
- Vaccine Ontology ID: VO_0000029
- CDC CVX code: 20, 106
- Type: Toxoid vaccine
- Status: Licensed
- Location Licensed: USA (License #1726)
- Host Species for Licensed Use: Human
- Antigen: Isotonic suspension of pertussis antigens and diphtheria and tetanus toxoids (FDA: DAPTACEL).
- Adjuvant:
- VO ID: VO_0000128
- Description: DAPTACEL is a vaccine indicated for active immunization against diphtheria, tetanus and pertussis as a five-dose series in infants and children 6 weeks through 6 years of age.
- Preparation: Clostridium tetani is grown in modified Mueller-Miller casamino acid medium without beef heart infusion. Tetanus toxin is detoxified with formaldehyde and purified by ammonium sulfate fractionation and diafiltration (FDA: DAPTACEL).
- Immunization Route: Intramuscular injection (i.m.)
- Storage: Should be stored at 2° to 8°C (35° to 46°F). DO NOT FREEZE.
- Approved Age for Licensed Use: DAPTACEL is a vaccine indicated for active immunization against diphtheria, tetanus and pertussis as a five dose series in infants and children 6 weeks through 6 years of age (prior to 7th birthday) (FDA: DAPTACEL).
- Contraindication: Severe allergic reaction (e.g. anaphylaxis) after a previous dose of any diphtheria toxoid, tetanus toxoid, or pertussis-containing vaccine, or any component of DAPTACEL, encephalopathy within 7 days of a previous pertussis-containing vaccine with no other identifiable cause and, progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized (FDA: DAPTACEL).
- Description: DAPTACEL is a vaccine indicated for active immunization against diphtheria, tetanus and pertussis as a five-dose series in infants and children 6 weeks through 6 years of age.
|
| References |
FDA: DAPTACEL: FDA: DAPTACEL [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101572.htm]
|
|
Infanrix |
| Vaccine Information |
- Vaccine Name: Infanrix
- Product Name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
- Tradename: Infanrix
- Manufacturer: GlaxoSmithKline Biologicals
- Vaccine Ontology ID: VO_0000064
- CDC CVX code: 20
- Type: Toxoid vaccine
- Status: Licensed
- Location Licensed: USA (License #1617 )
- Host Species for Licensed Use: Human
- Antigen: Diphtheria and tetanus toxoids and 3 pertussis antigens [inactivated pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (69 kiloDalton outer membrane protein)] (FDA: Infanrix).
- Adjuvant:
- Preparation: Tetanus toxin is produced by growing Clostridium tetani in a modified Latham medium derived from bovine casein. The toxin is detoxified with formaldehyde, concentrated by ultrafiltration, and purified by precipitation, dialysis, and sterile filtration (FDA: Infanrix).
- Immunization Route: Intramuscular injection (i.m.)
- Storage: Store INFANRIX refrigerated between 2° and 8°C (36° and 46°F). Do not freeze.
- Approved Age for Licensed Use: INFANRIX is indicated for active immunization against diphtheria, tetanus, and pertussis (whooping cough) as a 5-dose series in infants and children 6 weeks to 7 years of age (prior to seventh birthday). INFANRIX should not be administered to any infant before the age of 6 weeks, or to individuals 7 years of age or older (FDA: Infanrix).
- Contraindication: Hypersensitivity to any component of the vaccine is a contraindication, the vaccine should not be administered to anyone with encephalopathy, progressive neurological disorders, or an allergic reaction to a previous dose (FDA: Infanrix).
- Description: The vaccine is an noninfectious, sterile combination of diphtheria and tetanus toxoids and 3 pertussis antigens [inactivated pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (69 kiloDalton outer membrane protein)] adsorbed onto aluminum hydroxide (FDA: Infanrix).
|
| References |
FDA: Infanrix: FDA: Infanrix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101568.htm]
|
|
Pediarix |
| Vaccine Information |
- Vaccine Name: Pediarix
- Product Name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined
- Tradename: Pediarix
- Manufacturer: GlaxoSmithKline Biologicals
- Vaccine Ontology ID: VO_0000082
- CDC CVX code: 110
- Type: Toxoid vaccine
- Status: Licensed
- Location Licensed: United States
- Host Species for Licensed Use: Human
- Adjuvant:
- Allergen: yeast, neomycin,polymyxin B
- Preparation: The diphtheria toxin is produced by growing Corynebacterium diphtheriae in Fenton medium containing a bovine extract. The diphtheria, tetanus, and pertussis antigens are individually adsorbed onto aluminum hydroxide then diluted and combined to produce the final formulated vaccine (FDA: Pediarix).
- Immunization Route: Intramuscular injection (i.m.)
- Storage: The vaccine should be refrigerated between 2º and 8ºC (36º and 46ºF). Do not freeze.
- Approved Age for Licensed Use: PEDIARIX is indicated for active immunization against diphtheria, tetanus, pertussis (whooping cough), all known subtypes of hepatitis B virus, and poliomyelitis caused by poliovirus Types 1, 2, and 3 as a three-dose primary series in infants born of HBsAg-negative mothers, beginning as early as 6 weeks of age. PEDIARIX should not be administered to any infant before the age of 6 weeks, or to individuals 7 years of age or older.
- Contraindication: Hypersensitivity to any component of the vaccine, including yeast, neomycin, and polymyxin B, is a contraindication. The vaccine should also not be administered to anyone with a previous allergic reaction to a dose of the vaccine (FDA: Pediarix).
- Description: It contains diphtheria and tetanus toxoids, 3 pertussis antigens (inactivated pertussis toxin [PT] and formaldehyde-treated filamentous hemagglutinin [FHA] and pertactin [69 kiloDalton outer membrane protein]), hepatitis B surface antigen, plus poliovirus Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett) (FDA: Pediarix).
|
| References |
FDA: Pediarix: FDA: Pediarix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm146759.htm]
|
|
Tripedia |
| Vaccine Information |
- Vaccine Name: Tripedia
- Product Name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
- Tradename: Tripedia
- Manufacturer: Sanofi Pasteur, Inc.
- Vaccine Ontology ID: VO_0000112
- CDC CVX code: 20
- Type: Toxoid vaccine
- Status: Licensed
- Location Licensed: USA (FDA License #1725)
- Host Species for Licensed Use: Human
- Adjuvant:
- VO ID: VO_0000193
- Description: Tripedia vaccine combines diptheria and tetanus toxoids with purified pertussis antigens. It consists of 3 doses administered at intervals of 4-8 weeks (FDA: Tripedia).
- Immunization Route: Intramuscular injection (i.m.)
- Storage: Store between 2 and 8 degrees Celsius. DO NOT FREEZE.
- Approved Age for Licensed Use: Tripedia vaccine is indicated for active immunization against diphtheria, tetanus, and pertussis simultaneously in infants and children 6 weeks to 7 years of age (prior to seventh birthday). Due to substantial risks of complications of the disease, completion of a primary series of pertussis vaccine early in life is strongly recommended (FDA: Tripedia).
- Contraindication: This vaccine should not be administered to anyone with a known hypersensitivity to any component of the vaccine.
- Description: Tripedia vaccine combines diptheria and tetanus toxoids with purified pertussis antigens. It consists of 3 doses administered at intervals of 4-8 weeks (FDA: Tripedia).
|
| References |
FDA: Tripedia: FDA: Tripedia [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101565.htm]
|
|
